Authors:
Schellens, JHM
Dombernowsky, P
Cassidy, J
Epelbaum, R
Dirix, L
Cox, EH
Wanders, J
Calabresi, F
Paridaens, R
Monfardini, S
Wolff, J
Loos, WJ
Verweij, J
Pavlidis, N
Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590
Authors:
Paltiel, O
Schmit, T
Adler, B
Rachmilevitz, EA
Polliack, A
Cohen, A
Haim, N
Ben Shachar, M
Epelbaum, R
Barchana, M
Cohen, R
Ben Yehuda, D
Citation: O. Paltiel et al., The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-hodgkin lymphoma - Results and limitations of a registry-linked study, CANCER, 88(10), 2000, pp. 2357-2366
Authors:
Haim, N
Drumea, K
Epelbaum, R
Ben-Shahar, M
Citation: N. Haim et al., Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy innon-Hodgkin lymphoma, AM J CL ONC, 22(1), 1999, pp. 47-50
Authors:
Front, D
Bar-Shalom, R
Mor, M
Haim, N
Epelbaum, R
Frenkel, A
Gaitini, D
Kolodny, GM
Israel, O
Citation: D. Front et al., Hodgkin disease: Prediction of outcome with Ga-67 scintigraphy after one cycle of chemotherapy, RADIOLOGY, 210(2), 1999, pp. 487-491